Your email has been successfully added to our mailing list.

×
0.0241935483870968 -0.00806451612903226 0.00806451612903226 -0.0161290322580645 0.0403225806451613 0.0887096774193549 0.0564516129032259 0.0403225806451613
Stock impact report

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Clovis Oncology, Inc. (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
Company Research Source: Business Wire
TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM achieved the primary endpoint of improved radiographic progression-free survival (rPFS) by independent radiology review (IRR)– Median rPFS of 11.2 months for Rubraca vs 6.4 months for control group in the BRCA subgroup– Median rPFS of 10.2 months for Rubraca vs 6.4 months for control group in the ITT population (inclusive of all patients with a BRCA or ATM mutation enrolled in TRITON3)Safety profile of Rubraca observed in TRITON3 was consistent with Rubraca labellingTRITON3 is the confirmatory study for Rubraca’s current US accelerated approval in mCRPC and will also serve as the basis of a supplemental New Drug Application (sNDA) for US label expansion to be submitted during Q1 2023TRITON3 data have been submitted for presentation at the Prostate Cancer Foundation Annual Scie Show less Read more
Impact Snapshot
Event Time:
CLVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CLVS alerts
Opt-in for
CLVS alerts

from News Quantified
Opt-in for
CLVS alerts

from News Quantified